CENTREXION THERAPEUTICS CORP

Profile

Company Names

CENTREXION THERAPEUTICS CORP
CENTREXION CORP

Addresses

200 STATE STREET, 6TH FLOOR, BOSTON, MA 02109

200 STATE STREET, 6TH FLOOR, BOSTON, MA 02109

200 STATE STREET, BOSTON, MA 02109

509 S. EXETER ST., SUITE 202, BALTIMORE, MD 21202

Phone Numbers

617-837-6911
410-522-8701
212-956-1111

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2013

State Incorporated:

DELAWARE

Total Amount Raised:

$187,227,026.00

Number of Funding Rounds:

12
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
12
2023-12-28 
$3,255,467.00 
$12,859,762.00 
$9,604,295.00 
Debt 
11
2023-11-14 
$2,300,000.00 
$2,300,000.00 
$0.00 
Debt 
10
2023-06-14 
$10,280,238.00 
$30,000,000.00 
$19,719,762.00 
Debt 
9
2022-05-24 
$29,140,000.00 
$29,140,000.00 
$0.00 
Debt 
8
2021-01-12 
$13,500,000.00 
$13,500,000.00 
$0.00 
Debt 
7
2017-12-18 
$69,566,532.00 
$69,566,532.00 
$0.00 
Equity 
6
2017-04-28 
$5,285,000.00 
INDEFINITE 
INDEFINITE 
 
5
2016-12-30 
$16,564,789.00 
$16,564,789.00 
$0.00 
Equity 
4
2016-06-14 
$11,163,500.00 
INDEFINITE 
INDEFINITE 
 
3
2016-04-08 
$6,905,000.00 
INDEFINITE 
INDEFINITE 
 
2
2016-03-01 
$10,516,500.00 
INDEFINITE 
INDEFINITE 
 
1
2013-11-20 
$8,750,000.00 
$8,750,000.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
SOL 
 
BARER, PH.D. 
DIRECTOR
KERRIE 
L. 
BRADY 
EXECUTIVE OFFICER
JAMES 
N. 
CAMPBELL 
EXECUTIVE OFFICER, DIRECTOR
JAMES 
N. 
CAMPBELL, M.D. 
EXECUTIVE OFFICER, DIRECTOR
DEZHI 
 
KANG, PH.D. 
DIRECTOR
JEFFREY 
B. 
KINDLER 
EXECUTIVE OFFICER, DIRECTOR
J. 
C. 
LOPEZ, M.D. 
DIRECTOR
J.C. 
 
LOPEZ, M.D. 
DIRECTOR
DANIEL 
 
MENDELSON 
DIRECTOR
ARNOLD 
L. 
ORONSKY 
DIRECTOR
RANDALL 
M. 
STEVENS 
EXECUTIVE OFFICER
JOSEPH 
R. 
SWEDISH 
DIRECTOR
SHAWN 
 
TOMASELLO 
DIRECTOR
SHENGDA 
 
ZAN 
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2023-12-28 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2023-11-14 
D/A
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2023-06-14 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2023-06-14 
D/A
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2022-05-24 
D/A
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2022-05-24 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2022-05-24 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2021-01-12 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-12-18 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2017-04-28 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2016-12-30 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2016-06-14 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2016-04-08 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2016-03-01 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-11-20 
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-11-20 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-11-20 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
MAXIM GROUP LLC
NONE
NONE
FCC LTD.
NONE
NA
NONE
MAXIM GROUP LLC
NONE
NONE
LEERINK PARTNERS LLC
CIM SECURITIES, LLC
BROOKLINE CAPITAL MARKETS
NONE
MAXIM GROUP LLC
N/A
NONE